Juan Carlos Montejo

Hospital 12 de Octubre, Madrid, Madrid, Spain

Are you Juan Carlos Montejo?

Claim your profile

Publications (7)17.51 Total impact

  • Article: Isolation of Aspergillus lentulus in Spain from a critically ill patient with chronic obstructive pulmonary disease.
    [show abstract] [hide abstract]
    ABSTRACT: Aspergillus lentulus was first described in the year 2005, and since it cannot be phenotypically distinguished from Aspergillus fumigatus, it is conceivable that earlier descriptions (before 2005) could be attributed to this new species. Currently invasive infections caused by A. lentulus are rare and very few cases have been previously published in neutropenic patients, all of them with fatal outcome. Here we report a critically ill non neutropenic patient with chronic obstructive pulmonary disease (COPD) who was admitted to the medical intensive care unit with an exacerbation of COPD and who had been treated with long term corticosteroids. A. fumigatus was cultured from two bronchial aspirates and in a third bronchial aspirate both A. lentulus and A. fumigatus were isolated. On two consecutive days detection of galactomannan in serum was negative whilst detection of (1-3) beta-D glucan was positive (> 518 pg/ml). Minimal inhibitory concentrations (MIC) for itraconazole, voriconazole, caspofungin and amphotericin B were high for this strain of A. lentulus. Given the high MIC values of A. lentulus to available antifungals, the accurate identification of this new species is warranted. To our knowledge, this is the first report of the isolation of A. lentulus in a non-neutropenic critically ill patient, although we note that since it was isolated only once from respiratory specimens, its implication as an etiologic agent of infection for this patient remains to be established.
    Revista Iberoamericana de Micología 12/2008; 25(4):246-9. · 1.16 Impact Factor
  • Article: The early phase of the minute ventilation recovery curve predicts extubation failure better than the minute ventilation recovery time.
    [show abstract] [hide abstract]
    ABSTRACT: To determine, in patients who had successful outcomes in spontaneous breathing trials (SBTs), whether the analysis of the minute ventilation (Ve) recovery time obtained by minute-by-minute sequential monitoring after placing the patient back on mechanical ventilation (MV) may be useful in predicting extubation outcome. Twelve-month prospective observational study. Medical-surgical ICU of a university hospital. Ninety-three patients receiving > 48 h of MV. Baseline respiratory parameters (ie, respiratory rate, tidal volume, and Ve) were measured under pressure support ventilation prior to the SBT. After tolerating the SBT, patients again received MV with their pre-SBT ventilator settings, and respiratory parameters were recorded minute by minute. Seventy-four patients (80%) were successfully extubated, and 19 patients (20%) were reintubated. Reintubated patients were similar to non-reintubated patients in baseline respiratory parameters and baseline variables, except for age and COPD diagnosis. The recovery time needed to reduce Ve to half the difference between the Ve measured at the end of a successful SBT and basal Ve (RT50%DeltaVe) was lower in patients who had undergone successful extubation than in those who had failed extubation (mean [+/- SD] time, 2.7 +/- 1.2 vs 10.8 +/- 8.4 min, respectively; p < 0.001). Multiple logistic regression adjusted for age, sex, comorbid status, diagnosis (ie, neurocritical vs other), and severity of illness revealed that neurocritical disease (odds ratio [OR], 7.6; p < 0.02) and RT50%DeltaVe (OR, 1.7; p < 0.01) were independent predictors of extubation outcome. The area under the receiver operating characteristic curve for the predictive model was 0.89 (95% confidence interval, 0.81 to 0.96). Determination of the RT50%DeltaVe at the bedside may be a useful adjunct in the decision to extubate, with better results found in nonneurocritical patients.
    Chest 05/2007; 131(5):1315-22. · 5.25 Impact Factor
  • Source
    Article: Liver dysfunction associated with artificial nutrition in critically ill patients.
    [show abstract] [hide abstract]
    ABSTRACT: Liver dysfunction associated with artificial nutrition in critically ill patients is a complication that seems to be frequent, but it has not been assessed previously in a large cohort of critically ill patients. We conducted a prospective cohort study of incidence in 40 intensive care units. Different liver dysfunction patterns were defined: (a) cholestasis: alkaline phosphatase of more than 280 IU/l, gamma-glutamyl-transferase of more than 50 IU/l, or bilirubin of more than 1.2 mg/dl; (b) liver necrosis: aspartate aminotransferase of more than 40 IU/l or alanine aminotransferase of more than 42 IU/l, plus bilirubin of more than 1.2 mg/dl or international normalized ratio of more than 1.4; and (c) mixed pattern: alkaline phosphatase of more than 280 IU/l or gamma-glutamyl-transferase of more than 50 IU/l, plus aspartate aminotransferase of more than 40 IU/l or alanine aminotransferase of more than 42 IU/l. Seven hundred and twenty-five of 3,409 patients received artificial nutrition: 303 received total parenteral nutrition (TPN) and 422 received enteral nutrition (EN). Twenty-three percent of patients developed liver dysfunction: 30% in the TPN group and 18% in the EN group. The univariate analysis showed an association between liver dysfunction and TPN (p < 0.001), Multiple Organ Dysfunction Score on admission (p < 0.001), sepsis (p < 0.001), early use of artificial nutrition (p < 0.03), and malnutrition (p < 0.01). In the multivariate analysis, liver dysfunction was associated with TPN (p < 0.001), sepsis (p < 0.02), early use of artificial nutrition (p < 0.03), and calculated energy requirements of more than 25 kcal/kg per day (p < 0.05). TPN, sepsis, and excessive calculated energy requirements appear as risk factors for developing liver dysfunction. Septic critically ill patients should not be fed with excessive caloric amounts, particularly when TPN is employed. Administering artificial nutrition in the first 24 hours after admission seems to have a protective effect.
    Critical care (London, England) 02/2007; 11(1):R10. · 4.61 Impact Factor
  • Article: [Systemic antifungals. Pharmacodynamics and pharmacokinetics].
    Mercedes Catalán, Juan Carlos Montejo
    [show abstract] [hide abstract]
    ABSTRACT: Invasive fungal infections are important causes of morbidity and mortality in critically ill non neutropenic patients. For many years, amphotericin B and flucytosine have been the only available antifungal agents for invasive fungal infections. Fortunately, the antifungal armamentarium has increased during the past two decades with the addition of several new agents. In addition to itraconazole and fluconazole, lipid formulations of amphotericin B, voriconazole, and caspofungin have been recently licensed. These various antifungal agents differ in their pharmacokinetic and pharmacodynamic profile.
    Revista Iberoamericana de Micología 04/2006; 23(1):39-49. · 1.16 Impact Factor
  • Article: [Importance of invasive candidiasis in critical non-neutropenic patients].
    Juan Carlos Montejo, Amalia Del Palacio
    [show abstract] [hide abstract]
    ABSTRACT: Invasive candidiasis (IC) is the most frequent fungal infection in high risk patients in intensive care setting. IC is associated with high attributable mortality and increased healthcare cost. In this review current, epidemiological, diagnostic and clinical management is updated and discussed in the critically ill non netropenic patient.
    Revista Iberoamericana de Micología 04/2006; 23(1):2-3. · 1.16 Impact Factor
  • Article: [Prevention of invasive candidiasis in the critically ill non neutropenic patient].
    Juan Carlos Montejo, Mercedes Catalán, Amalia Del Palacio
    [show abstract] [hide abstract]
    ABSTRACT: Prevention of invasive candidiasis (IC) in the setting of critically ill non neutropenic patients should be based on evidenced-based recommendations, namely improved hand hygiene, optimal catheter care, and rational and reduced use of broad-spectrum antibiotics. Concomitant interventions aimed at reducing risk factors are important to decrease IC.
    Revista Iberoamericana de Micología 04/2006; 23(1):32-4. · 1.16 Impact Factor
  • Source
    Article: Effect of a glutamine-enriched enteral diet on intestinal permeability and infectious morbidity at 28 days in critically ill patients with systemic inflammatory response syndrome: a randomized, single-blind, prospective, multicenter study.
    [show abstract] [hide abstract]
    ABSTRACT: We investigated the effect of a glutamine-enriched enteral diet on intestinal permeability and infectious morbidity and mortality in critically ill patients who developed systemic inflammatory response syndrome after an acute event. Eleven intensive care units in tertiary-care hospitals participated in a prospective, randomized, single blind, multicenter trial. Eighty-four patients with systemic inflammatory response syndrome of any etiology were randomly allocated to receive a glutamine-enriched enteral diet or a control diet without glutamine.Most patients received the planned caloric intake. The number of infected patients was smaller in the glutamine group than in the control group (11 versus 17 patients, P < 0.05), with a relative risk of 0.5 (95% confidence interval = 0.3-0.9). The most frequent infection was nosocomial pneumonia, with 11 (33%) patients in the control group and 6 (14%) in the glutamine group. There were no differences with respect to other infections, mortality, or length of stay. Intestinal permeability as assessed by the lactulose-mannitol test was unchanged in both groups.Glutamine-enriched enteral diets can decrease nosocomial infections in patients with systemic inflammatory response syndrome.
    Nutrition 09/2002; 18(9):716-21. · 3.03 Impact Factor